[
  {
    "ts": null,
    "headline": "OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results",
    "summary": "Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies",
    "url": "https://finnhub.io/api/news?id=800f961eed6f907f9bb6f3dc8dec58f5b674420bbf5e834da8eb448cc29fce9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772139900,
      "headline": "OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results",
      "id": 139239950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies",
      "url": "https://finnhub.io/api/news?id=800f961eed6f907f9bb6f3dc8dec58f5b674420bbf5e834da8eb448cc29fce9c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders",
    "summary": "Regeneron Renews its Science Talent Search Sponsorship for Another 10 Years Regeneron is renewing the title sponsorship of the Regeneron Science Talent Search, the United States’ oldest and most prestigious science and mathematics competition for high school seniors. The company is committing $150 million for the next 10 years. Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for S",
    "url": "https://finnhub.io/api/news?id=1747c020f78d2ccac72ee932fb6aea69b6fda9890f61c679bd3a79d9f1c60fc6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772125380,
      "headline": "Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders",
      "id": 139237219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Renews its Science Talent Search Sponsorship for Another 10 Years Regeneron is renewing the title sponsorship of the Regeneron Science Talent Search, the United States’ oldest and most prestigious science and mathematics competition for high school seniors. The company is committing $150 million for the next 10 years. Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for S",
      "url": "https://finnhub.io/api/news?id=1747c020f78d2ccac72ee932fb6aea69b6fda9890f61c679bd3a79d9f1c60fc6"
    }
  },
  {
    "ts": null,
    "headline": "Why Is CRISPR Therapeutics Stock Surging Thursday?",
    "summary": "CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased patient treatment and analyst confidence.",
    "url": "https://finnhub.io/api/news?id=26f931442be9b6328f1407d639df42ff827d5cb462764189066f69661c22af2b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772117146,
      "headline": "Why Is CRISPR Therapeutics Stock Surging Thursday?",
      "id": 139246942,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/26/Crispr-Therapeutics.jpeg?width=2048&height=1536",
      "related": "REGN",
      "source": "Benzinga",
      "summary": "CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased patient treatment and analyst confidence.",
      "url": "https://finnhub.io/api/news?id=26f931442be9b6328f1407d639df42ff827d5cb462764189066f69661c22af2b"
    }
  }
]